文献速递心力衰竭与心肌病

解读堪萨斯城心肌病问卷中的群体平均治疗效应:患者水平Meta分析

Interpreting Population Mean Treatment Effects in the Kansas City Cardiomyopathy Questionnaire: A Patient-Level Meta-Analysis.
PubMed 文献 · JAMA Cardiol · 2025-01-01

该研究基于11项随机临床试验共9977例患者进行患者水平分析,评估KCCQ平均治疗效应与临床重要改善比例之间的关联。结果显示组间平均KCCQ-OSS差异与临床重要改善的绝对差异强相关(Spearman相关系数0.76-0.92)。平均治疗效应2.5分对应改善≥5分的绝对差异6.0%(95%PI 4.0%-8.1%)和改善≥10分的绝对差异5.0%(95%PI 3.1%-7.0%)。

要点

  • 平均KCCQ-OSS差异与临床重要改善比例强相关。
  • 平均2.5分差异对应NNT为17(改善≥5分)和20(改善≥10分)。
  • 仅凭群体平均效应推断临床影响可能误导。

核心结论

  • 基于群体平均治疗效应推断临床影响可能误导,即使小的组间差异也可能反映个体患者的临床重要获益。
  • 临床试验应明确描述各治疗组内患者水平KCCQ变化的分布,以支持结果的临床解读。

研究设计与样本

  • 患者水平分析纳入11项随机临床试验共9977例患者,并在7项额外试验中验证。
  • 分析时间为2023年7月1日至9月15日,无目标日期范围,纳入研究为有患者水平数据者。

主要发现

  • 组间平均KCCQ-OSS差异与临床重要变化的绝对差异强相关(Spearman相关系数0.76-0.92)。
  • 平均KCCQ-OSS治疗效应2.5分(个体最小重要差异的一半)对应改善≥5分的绝对差异6.0%(95%PI 4.0%-8.1%)。
  • 平均KCCQ-OSS治疗效应2.5分对应改善≥10分的绝对差异5.0%(95%PI 3.1%-7.0%)。
  • 上述对应NNT分别为17(95%PI 12-25)和20(95%PI 14-33)。

关键数值与推荐

  • KCCQ各领域转换为0-100分范围,分数越高代表健康状况越好。
  • 临床重要改善定义为KCCQ评分改善≥5分,中等至大幅改善定义为≥10分。

临床怎么用

  • 解读心衰试验KCCQ结果时,应关注患者水平变化分布而非仅看平均效应。
  • 小平均差异可能对应可观的临床重要改善比例,需结合NNT理解治疗获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a commonly used outcome in heart failure trials. While comparing means between treatment groups improves statistical power, mean treatment effects do not necessarily reflect the clinical benefit experienced by individual patients. OBJECTIVE: To evaluate the association between mean KCCQ treatment effects and the proportions of patients experiencing clinically important improvements across a range of clinical trials and heart failure etiologies. DESIGN, SETTING, AND PARTICIPANTS: A patient-level analysis of 11 randomized clinical trials, including 9977 patients, was performed to examine the association between mean treatment effects and the KCCQ Overall Summary Score (OSS) and the absolute differences in the proportions of patients experiencing clinically important (≥5 points) and moderate to large (≥10 points) improvements. There was no target date range, and included studies were those for which patient-level data were available. Validation was performed in 7 additional trials. The data were analyzed between July 1 and September 15, 2023. MAIN OUTCOMES AND MEASURES: Proportion of patients experiencing an improvement of 5 or more and 10 or more points in their KCCQ score (with each domain transformed to a range of 0 to 100 points, where higher scores represent better health status). RESULTS: Group mean KCCQ-OSS differences were strongly correlated with absolute differences in clinically important changes (Spearman correlations 0.76-0.92). For example, a mean KCCQ-OSS treatment effect of 2.5 points (half of a minimally important difference for an individual patient) was associated with an absolute difference of 6.0% (95% prediction interval [PI], 4.0%-8.1%) in the proportion of patients improving 5 or more points and 5.0% (95% PI, 3.1%-7.0%) in the proportion improving 10 or more points, corresponding to a number needed to treat of 17 (95% PI, 12-25) and 20 (95% PI, 14-33), respectively. CONCLUSIONS AND RELEVANCE: Inferences about clinical impacts based on population-level mean treatment effects may be misleading, since even small between-group differences may reflect clinically important treatment benefits for individual patients. Results of this study suggest that clinical trials should explicitly describe the distributions of KCCQ change at the patient level within treatment groups to support the clinical interpretation of their results.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Abdel Jawad M, Jones PG, Arnold SV, et al. Interpreting Population Mean Treatment Effects in the Kansas City Cardiomyopathy Questionnaire: A Patient-Level Meta-Analysis. JAMA Cardiol. 2025. PMID: 39546393. doi:10.1001/jamacardio.2024.4470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。